Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

[1]  A. Imagawa,et al.  Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. , 2019, Endocrine journal.

[2]  F. Grossi,et al.  RETRACTED ARTICLE: Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study , 2019, Endocrine.

[3]  R. Chiari,et al.  Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis , 2018, Journal of Cancer Research and Clinical Oncology.

[4]  R. Langer,et al.  Histology of Nivolumab-Induced Thyroiditis. , 2018, Thyroid : official journal of the American Thyroid Association.

[5]  Y. Ohe,et al.  Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab , 2018, Cancer science.

[6]  F. Hodi,et al.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.

[7]  G. Rabinowits,et al.  A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. , 2018, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[8]  J. Larkin,et al.  Acute management of the endocrine complications of checkpoint inhibitor therapy , 2018 .

[9]  M. Marinò,et al.  A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab , 2018, Journal of Endocrinological Investigation.

[10]  J. Larkin,et al.  SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy , 2018, Endocrine connections.

[11]  J. Brahmer,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.

[12]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Akiyama,et al.  Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study , 2018, Journal of the Endocrine Society.

[14]  D. Elashoff,et al.  Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center , 2018, Cancer Immunology Research.

[15]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[16]  Yoshiya Tanaka,et al.  Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. , 2017, Thyroid.

[17]  Kaoru Tanaka,et al.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.

[18]  A. Dietz,et al.  Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms , 2017, The Journal of clinical endocrinology and metabolism.

[19]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[20]  C. Rudin,et al.  Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[22]  R. Sullivan,et al.  Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  B. Neyns,et al.  Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab , 2016, The Journal of clinical endocrinology and metabolism.

[24]  D. Rodríguez-Abreu,et al.  Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. , 2016, The oncologist.

[25]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[26]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[27]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[28]  D. Hinkle,et al.  Drug-induced graves disease from CTLA-4 receptor suppression. , 2011, Ophthalmic plastic and reconstructive surgery.

[29]  T. Jørgensen,et al.  The association between hypoechogenicity or irregular echo pattern at thyroid ultrasonography and thyroid function in the general population. , 2006, European journal of endocrinology.

[30]  A. Pinchera,et al.  Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dysfunction in apparently healthy subjects , 2001, Journal of endocrinological investigation.

[31]  G. Daniels,et al.  Chronic autoimmune thyroiditis. , 1996, The New England journal of medicine.

[32]  Y. Yonekura,et al.  Sonography of Hashimoto's thyroiditis , 1986, Journal of clinical ultrasound : JCU.

[33]  S. Onoyama,et al.  Echographic findings and histological feature of the thyroid: a reverse relationship between the level of echo-amplitude and lymphocytic infiltration. , 1985, Endocrinologia japonica.

[34]  U. Bogner,et al.  Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto's thyroiditis but not Graves' disease. , 1984, The Journal of clinical endocrinology and metabolism.

[35]  Y. Koh,et al.  Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. , 2018, Lung cancer.

[36]  D. Hinkle,et al.  Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression. , 2014, Ophthalmic plastic and reconstructive surgery.

[37]  J. Manson,et al.  Prospective Study of , 2007 .

[38]  L. Hegedüs,et al.  Thyroid cytotoxic antibodies in atrophic and goitrous autoimmune thyroiditis. , 1995, European journal of endocrinology.

[39]  A Pinchera,et al.  Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. , 1991, The Journal of clinical endocrinology and metabolism.